NCT02191462已完成1 期
A Randomized, Double-blind, Cross-over Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- t1/2 (terminal half-life)
研究概览
简要总结
The purpose of this study in to analyse the way in which the body processes Niagen (nicotinamide riboside) in healthy people. Blood and urine samples from subjects who are given a dose of Niagen will be analyzed for metabolites over the 24 hours after taking the dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy Male or female age 30-55 years
- •BMI 18.5-29.9 kg/m2
- •If female, subject is not of child bearing potential, OR Females of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result.
- •Healthy as determined by laboratory results and medical history
- •Agrees to maintain current level of physical activity throughout the study
- •Agrees to avoid vitamins and St. John's Wort for 30 days prior to enrollment and during the study
- •Agrees to avoid nutritional yeast, whey proteins, energy drinks, dairy products, grapefruit and grapefruit juice and alcohol 7 days prior to enrollment and during study
- •Has given voluntary, written, informed consent to participate in the study
排除标准
- •Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial.
- •Use of natural health products (NHPs)/dietary supplements within 7 days prior to randomization and during the course of the study.
- •Use of vitamins or St. John's Wort in the last 30 days before the study enrollment,
- •Use of natural health products containing Nicotinamide riboside within 7 days prior to randomization and during the course of the study
- •Use of nutritional yeast, whey proteins, energy drinks, grapefruit and grapefruit juice, dairy products, alcohol for 7 days prior to the study
- •Subjects who are smokers
- •Subjects with blood pressure ≥140/90
- •Use of blood pressure medications
- •Use of cholesterol lowering medications
- •Metabolic diseases or chronic diseases
- •Use of acute over the counter medication within 72 hours of test product dosing
- •Unstable medical conditions as determined by the Qualified Investigator
- •Immunocompromised individuals such as subjects that have undergone organ transplantation or subjects diagnosed with human immunodeficiency virus (HIV)
- •Clinically significant abnormal lab results at screening (e.g. AST and/or ALT > 2 x ULN, and/or bilirubin > 2 x ULN) will be assessed by the Medical Investigator
- •Subjects who have planned surgery during the course of the trial
- •History of or current diagnosis of any cancer (except for successfully treated basal cell carcinoma) diagnosed less than 5 years prior to screening. Subjects with cancer in full remission more than 5 years after diagnosis are acceptable
- •History of blood/bleeding disorders
- •Blood donation in the past 2 months
- •Alcohol abuse (>2 standard alcoholic drinks per day) or drug abuse within the past 6 months
- •Participation in a clinical research trial within 30 days prior to randomization
- •Allergy or sensitivity to study supplement ingredients or to any food or beverage provided during the study
- •Individuals who are cognitively impaired and/or who are unable to give informed consent.
- •Any other condition which in the Investigator's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose significant risk to the subject
结局指标
主要结局
t1/2 (terminal half-life)
时间窗: 24 hours
24 hour dosing period; 3 dosing periods each separated by 7 day washout
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study Investigating the Effects of Niagen™ in Healthy Adults.BioavailabilityNCT02712593KGK Science Inc.140
已完成
1 期
The Safety of a Hypolipidemic Agent in Healthy Normal VolunteersHealthyNCT01930240Cortria Corporation20
招募中
2 期
Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)Fatty LiverObesityHepatic FibrosisNCT06599918Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau30
已完成
1 期
Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge DrinkBinge DrinkingNutritional SupplementationHepatic SteatosisLiver InjuryNCT05882214Zhejiang Chinese Medical University22
已完成
不适用
Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive ImpairmentCognition Disorders in Old AgeMild Cognitive ImpairmentCognitive DeclineNCT04078178Steven E Arnold, MD61